

REGENERON PHARMACEUTICALS INC  
Form 8-K  
April 18, 2011

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K  
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 18, 2011 (April 18, 2011)

REGENERON PHARMACEUTICALS, INC.  
(Exact Name of Registrant as Specified in Charter)

New York	000-19034	13-3444607
(State or other jurisdiction of Incorporation)	(Commission File No.)	(IRS Employer Identification No.)

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707  
(Address of principal executive offices, including zip code)

(914) 347-7000  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

## Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

### Item 8.01 Other Events.

On April 18, 2011, Regeneron Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration (the “FDA”) has accepted for review the Company’s Biologics License Application (“BLA”) for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration and granted the Company's request for priority review of its BLA. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and incorporated by reference into this Item.

### Item 9.01 Financial Statements and Exhibits.

#### (d) Exhibits

- 99.1 Press Release Announcing that FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration, dated April 18, 2011.
-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 18, 2011

REGENERON PHARMACEUTICALS, INC.

By: /s/ Murray A. Goldberg  
Name: Murray A. Goldberg  
Title: Senior Vice President, Finance and  
Administration, Chief Financial Officer, Treasurer,  
and Assistant Secretary

---

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form 8-K

Exhibit Index

Number	Description
99.1	Press Release Announcing that FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration, dated April 18, 2011.

---